Alphamab Oncology (HK:9966) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology has announced the grant of 470,000 share options to its employees under its Post-IPO Share Option Scheme, with an exercise price set at HK$3.86 per share. These options are set to vest over four years, with the potential for employees to benefit from the company’s future growth if performance targets are met. The move is part of Alphamamab’s strategy to incentivize and retain key talent as it continues its development in the oncology sector.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.